AU - Kachhawa, Kamal
AU - Varma, Meena
AU - Kachhawa, Poonam
AU - Sahu, Ankita
AU - Shaikh, M.K.S.
AU - Kumar, Sanjay
TI - Study of Dyslipidemia and Cystatin C Levels as a Predictive Marker of Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients at a Teaching Hospital in Central India
PT - ORIG
DP - 2016 Jan 1
TA - Journal of Integrative Nephrology and Andrology
PG - 24-28
VI - 3
IP - 1
4099- http://www.journal-ina.com/article.asp?issn=2394-2916;year=2016;volume=3;issue=1;spage=24;epage=28;aulast=Kachhawa;type=0
4100- http://www.journal-ina.com/article.asp?issn=2394-2916;year=2016;volume=3;issue=1;spage=24;epage=28;aulast=Kachhawa
AB - Background and Objective: Diabetic nephropathy is the most common cause of microvascular chronic complication of Type 2 diabetes mellitus (T2DM), which is associated with considerable morbidity and mortality. Chronic kidney diseases (CKD) may result from diabetes mellitus (34%), hypertension (29%), glomerulonephritis (14%), and others (23%). The present study was undertaken to explore the possibility of the serum cystatin C level as a marker of early renal impairment in T2DM patient. Materials and Methods: The study was conducted in 75 patients of T2DM and 75 healthy individuals were included as control in this study. After 12 h fasting, 8 mL venous blood sample was collected and allowed to clot for h and serum was separated. Lipid profile and cystatin C level of serum were measured by using commercially available kit of auto analyzer. Results: The level of serum cystatin C was significantly increased in T2DM patients as compared to control. In T2DM patients, high-density lipoprotein cholesterol significantly decreased (P < 0.001), while other parameters of lipid profile were significantly increased (P < 0.001) as compared to control group. Conclusion: Present study suggests that cystatin C measurement in serum is a useful, practical, noninvasive tool for the evaluation of renal involvement in the course of diabetes, especially patients, and the study also shows significant lipoprotein abnormalities in T2DM patients when compared to control.